Scott Peter Owen

机构：McGill University Health Centre, McGill University · ORCID：0000-0002-9745-0555

发表论文 87 篇 · 总被引 1870 次 · h-index 19

代表论文

• Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC (2025 · New England Journal of Medicine · 被引 113)
• Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA (2024 · Annals of Oncology · 被引 89)
• Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial (2026 · Nature Medicine · 被引 54)
• LBA55 Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early analysis from the phase III MARIPOSA study (2024 · Annals of Oncology · 被引 46)
• OA02.03 Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study (2024 · Journal of Thoracic Oncology · 被引 9)
• MA12.07 Amivantamab Plus Lazertinib vs Osimertinib in First-Line, EGFR-Mutant Advanced NSCLC: Patient-relevant Outcomes from MARIPOSA (2024 · Journal of Thoracic Oncology · 被引 9)